Zimmer Biomet reports 4.0% rise in Q3 net sales to $1.824bn, facing ERP challenges and revising full-year 2024 guidance.

Zimmer Biomet reported a 4.0% rise in third-quarter net sales, totaling $1.824 billion, with diluted earnings of $1.23 per share. Adjusted earnings per share were $1.74, meeting analyst expectations. The company faces ERP implementation challenges and has revised its full-year 2024 guidance, lowering projected revenue growth and adjusted EPS. It plans to launch the Z1™ Femoral Hip System at the 2024 AAHKS meeting and recently acquired OrthoGrid Systems Inc.

October 30, 2024
12 Articles

Further Reading